Janssen announces new collaboration with PeptiDream

Janssen Pharmaceuticals has announced that it has signed up for access to PeptiDream's peptide discovery technology in a deal believed to be worth somewhere in the region of $1.15 billion (916 million pounds).

Janssen joins the likes of AstraZeneca, GlaxoSmithKline, Novartis and Sanofi as the latest new discovery partner of PeptiDream.

The pharmaceutical firm will be choosing metabolic and cardiovascular targets to explore, harnessing PeptiDream's Peptide Discovery Platform System to identify peptides that affect these targets.

From there, Janssen will be looking to develop new therapeutic peptides aimed at benefiting patients' health further down the line.

The deal means that Janssen will have the development and marketing rights to any new pharmaceutical products discovered as a result of this collaboration.

The Pharma Letter quotes PeptiDream's chief executive Kiichi Kubota as saying: "We greatly look forward to working with a world-renowned organisation like Janssen to leverage these capabilities to discover and develop the next generation of first-in-class and best-in-class therapeutics."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.

Image: daizuoxin via iStock